Pfizer Inc.’s general counsel will no longer oversee the company’s compliance program, under the terms of the company’s $2.3 billion settlement agreement resolving allegations that Pfizer’s executives and sales staff illegally marketed the painkiller Bextra and several other drugs.

Instead, the chief compliance officer at the world’s largest drug maker will report directly to the CEO. The move is required by Pfizer’s corporate integrity agreement with the office of the inspector general of the U.S. Department of Health and Human Services (HHS), which is part of the company’s civil and criminal settlement with the U.S. Department of Justice.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]